Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode
| dc.contributor.author | Lockbaum, Gordon J. | |
| dc.contributor.author | Henes, Mina | |
| dc.contributor.author | Lee, Jeong Min. | |
| dc.contributor.author | Timm, Jennifer | |
| dc.contributor.author | Nalivaika, Ellen A. | |
| dc.contributor.author | Thompson, Paul R | |
| dc.contributor.author | Yilmaz, Nese Kurt | |
| dc.contributor.author | Schiffer, Celia A. | |
| dc.date | 2022-08-11T08:08:11.000 | |
| dc.date.accessioned | 2022-08-23T15:45:20Z | |
| dc.date.available | 2022-08-23T15:45:20Z | |
| dc.date.issued | 2021-10-05 | |
| dc.date.submitted | 2021-09-30 | |
| dc.identifier.citation | <p>Lockbaum GJ, Henes M, Lee JM, Timm J, Nalivaika EA, Thompson PR, Kurt Yilmaz N, Schiffer CA. Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode. Biochemistry. 2021 Oct 5;60(39):2925-2931. doi: 10.1021/acs.biochem.1c00414. Epub 2021 Sep 10. PMID: 34506130; PMCID: PMC8457326. <a href="https://doi.org/10.1021/acs.biochem.1c00414">Link to article on publisher's site</a></p> | |
| dc.identifier.issn | 0006-2960 (Linking) | |
| dc.identifier.doi | 10.1021/acs.biochem.1c00414 | |
| dc.identifier.pmid | 34506130 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/27503 | |
| dc.description.abstract | Rupintrivir targets the 3C cysteine proteases of the picornaviridae family, which includes rhinoviruses and enteroviruses that cause a range of human diseases. Despite being a pan-3C protease inhibitor, rupintrivir activity is extremely weak against the homologous 3C-like protease of SARS-CoV-2. In this study, the crystal structures of rupintrivir were determined bound to enterovirus 68 (EV68) 3C protease and the 3C-like main protease (M(pro)) from SARS-CoV-2. While the EV68 3C protease-rupintrivir structure was similar to previously determined complexes with other picornavirus 3C proteases, rupintrivir bound in a unique conformation to the active site of SARS-CoV-2 M(pro) splitting the catalytic cysteine and histidine residues. This bifurcation of the catalytic dyad may provide a novel approach for inhibiting cysteine proteases. | |
| dc.language.iso | en_US | |
| dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34506130&dopt=Abstract">Link to Article in PubMed</a></p> | |
| dc.relation.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457326/ | |
| dc.subject | rupintrivir | |
| dc.subject | 3C cysteine proteases | |
| dc.subject | pan-3C protease inhibitor | |
| dc.subject | SARS-CoV-2 | |
| dc.subject | Biochemistry | |
| dc.subject | Chemistry | |
| dc.subject | Enzymes and Coenzymes | |
| dc.subject | Infectious Disease | |
| dc.subject | Microbiology | |
| dc.subject | Structural Biology | |
| dc.subject | Virus Diseases | |
| dc.subject | Viruses | |
| dc.title | Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode | |
| dc.type | Journal Article | |
| dc.source.journaltitle | Biochemistry | |
| dc.source.volume | 60 | |
| dc.source.issue | 39 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/covid19/303 | |
| dc.identifier.contextkey | 25210840 | |
| html.description.abstract | <p>Rupintrivir targets the 3C cysteine proteases of the picornaviridae family, which includes rhinoviruses and enteroviruses that cause a range of human diseases. Despite being a pan-3C protease inhibitor, rupintrivir activity is extremely weak against the homologous 3C-like protease of SARS-CoV-2. In this study, the crystal structures of rupintrivir were determined bound to enterovirus 68 (EV68) 3C protease and the 3C-like main protease (M(pro)) from SARS-CoV-2. While the EV68 3C protease-rupintrivir structure was similar to previously determined complexes with other picornavirus 3C proteases, rupintrivir bound in a unique conformation to the active site of SARS-CoV-2 M(pro) splitting the catalytic cysteine and histidine residues. This bifurcation of the catalytic dyad may provide a novel approach for inhibiting cysteine proteases.</p> | |
| dc.identifier.submissionpath | covid19/303 | |
| dc.contributor.department | Thompson Lab | |
| dc.contributor.department | Schiffer Lab | |
| dc.contributor.department | Department of Biochemistry and Molecular Pharmacology | |
| dc.source.pages | 2925-2931 |